Flag of the European Union EU Clinical Trials Register Help

Clinical trials for AMD AND Age-Related Macular Degeneration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    193 result(s) found for: AMD AND Age-Related Macular Degeneration. Displaying page 2 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-021777-37 Sponsor Protocol Number: Lucentis-LucERG Start Date*: 2010-09-27
    Sponsor Name:Universitätsklinikum Schleswig-Holstein (UK-SH)
    Full Title: "A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with we...
    Medical condition: Retinal function in patients with wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003333-15 Sponsor Protocol Number: CRFB002AIT02 Start Date*: 2013-11-15
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 12 months, prospective, multicenter, open-label, single arm interventional study assessing the safety and tolerability of 0.5 mg ranibizumab in mono/bilateral wet AMD patients in eyes with BCVA b...
    Medical condition: Mono/bilateral Wet Age related Macular Degeneration (wAMD) in eyes with Best Corrected Visual Acuity (BCVA) below 2/10 and/or second affected eye .
    Disease: Version SOC Term Classification Code Term Level
    16.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003204-12 Sponsor Protocol Number: ICI21/00025 Start Date*: 2022-03-16
    Sponsor Name:Consorcio PSMAR
    Full Title: Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-...
    Medical condition: age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004292-35 Sponsor Protocol Number: 06NB37 Start Date*: 2007-03-08
    Sponsor Name:Kings College Hospital NHS Foundation Trust
    Full Title: A pillot study to examine the safety and efficacy of intravitreal ranubizimab/dexamethasone administration and oral minocycline in addition to Visudyne (verteporfin) photdynamic therapy for subfove...
    Medical condition: Age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004721-23 Sponsor Protocol Number: VIBERA Start Date*: 2007-11-14
    Sponsor Name:Klinikum Bremen-Mitte gGmbH
    Full Title: Prevention of vision loss in patients with age-related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting
    Medical condition: age-related neovascular macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004523-16 Sponsor Protocol Number: GR42691 Start Date*: 2021-04-12
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Medical condition: Neovascular age-related macular degeneration (nAMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10025410 Macular degeneration (senile) of retina, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) DE (Completed) AT (Completed) DK (Completed) HU (Completed) PL (Completed) NL (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-000518-23 Sponsor Protocol Number: OPH1007 Start Date*: 2015-10-20
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista® (Anti-PDGFBB pegylated aptamer) administered in combination w...
    Medical condition: Subfoveal neovascular age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006358-86 Sponsor Protocol Number: ATG003-201 Start Date*: 2007-04-27
    Sponsor Name:CoMentis, Inc., USA
    Full Title: A PHASE II RANDOMIZED, DOUBLE-MASKED, STUDY COMPARING THE SAFETY AND EFFICACY OF ATG003 (MECAMYLAMINE HCL) 1.0% and 0.3% OPHTHALMIC SOLUTIONS TO PLACEBO IN PATIENTS WITH NEOVASCULAR ("WET") AGE-REL...
    Medical condition: Neovascular ("wet") Age-related Macular Degeneration (NV- AMD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003042-15 Sponsor Protocol Number: ACU301 Start Date*: 2007-10-12
    Sponsor Name:Opko Health, Incorporated
    Full Title: A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® c...
    Medical condition: Patients with subfoveal choroidal neovascularization associated with Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) ES (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000379-41 Sponsor Protocol Number: RLBUHT3407 Start Date*: 2007-05-22
    Sponsor Name:Royal Liverpool & Broadgreen University hospital
    Full Title: Liverpool Avastin Dose Response and Retreatment Study
    Medical condition: Exudative senile macular degeneration of the retina
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003261-14 Sponsor Protocol Number: R01 Start Date*: 2006-08-28
    Sponsor Name:Retinaklinikken Omnia
    Full Title: A randomized pilot study comparing the safety and efficacy of intravireal triamcinolone acetonide given 7 days prior to or after Photodynamic therapy with Visudyne in patients with subfoveal choroi...
    Medical condition: Patients with age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025409 Macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004608-78 Sponsor Protocol Number: LSFG-1.2 Start Date*: 2017-03-03
    Sponsor Name:Kepler University Hospital, Institute of Ophthalmology
    Full Title: The Effect of Intravitreal Aflibercept on Ocular Perfusion – a Pilot Study
    Medical condition: Exudative AMD
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004853 10025411 Macular degeneration senile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018637-21 Sponsor Protocol Number: 1 Start Date*: 2013-11-20
    Sponsor Name:Universitätsklinikum Schleswig-Holstein UKSH
    Full Title: Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrha...
    Medical condition: exsudative age-related macular degeneration with acut submacular hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10055305 Macula lutea hemorrhage LLT
    16.1 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005607-18 Sponsor Protocol Number: OPHT-011007 Start Date*: 2009-04-02
    Sponsor Name:Ursapharm Arzneimittel GmbH & Co KG
    Full Title: An open study comparing the effects of moxaverine on ocular blood flow in patients with age- related macular degeneration, primary open angle glaucoma and healthy control subjects
    Medical condition: glaucoma age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036719 Primary open angle glaucoma LLT
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004487-53 Sponsor Protocol Number: 2312/2007 Start Date*: 2007-12-13
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Pilot study of association of VEGF polymorphisms with clinical efficacy and tolerability of therapy in patients affected by exudative (neovascular) age-related macular degeneration.
    Medical condition: Exudative and atrophic age-related macular degeneration.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-006014-18 Sponsor Protocol Number: 1419 Start Date*: 2005-12-15
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Macular structure and function after intravitreal injection of bevacizumab for wet macular degeneration a interventional study.
    Medical condition: Macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025409 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017324-11 Sponsor Protocol Number: CRFB002ADE09T Start Date*: 2010-03-08
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Wirksamkeit von Ranibizumab bei Patienten mit CHORIOIDALER NEOVASKULARISATION (CNV), als Folge einer altersbedingten Makuladegeneration (AMD), bei einer Gabe alle zwei Monate gegenüber der Behandlu...
    Medical condition: In der vorliegenden Studie wird in beiden Studienarmen Ranibizumab injiziert, es gibt keine Sham Gruppe. Randomisiert wird das Muster der Injektion (fixe Injektion alle 2 Monate versus Injektion be...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006290-90 Sponsor Protocol Number: AU-06102G Start Date*: 2008-10-10
    Sponsor Name:Society (Institute) for clinical research
    Full Title: Subretinal Macugen for neovascular age-related macular degeneration (SUMANA)
    Medical condition: Neovascular (exudative) age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005091-17 Sponsor Protocol Number: 26285/13 Start Date*: 2014-02-05
    Sponsor Name:POLICLINICO GEMELLI
    Full Title: Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naïve patients WIth Neovascular age-related macular degeneration: pilot Study. –
    Medical condition: Wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000536-28 Sponsor Protocol Number: C-10-083 Start Date*: 2011-09-12
    Sponsor Name:Alcon Research Ltd.
    Full Title: Safety and efficacy study with ESBA1008 versus Lucentis for the treatment of exudative age-related macular degeneration
    Medical condition: wet age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 10 14:07:49 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA